Test Price
900 AED✅ Home Collection Available
Myeloproliferative Leukemia Mutation Screening (MPL – S505N; W515L) in UAE | 900 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing with dual‑confirmation LC‑MS/MS reflex for ambiguous variants.
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Complementary telephonic post‑test result interpretation session with a DHA‑licensed genetics advisor.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. Most major UAE insurers accepted.
Test Overview & Methodology
The MPL mutation screening precisely identifies somatic gain‑of‑function variants S505N and W515L in the thrombopoietin receptor gene – a cornerstone in diagnosing Philadelphia‑negative myeloproliferative neoplasms. This molecular assay uses gold‑standard Sanger sequencing with LC‑MS/MS reflex confirmation to deliver 99.9% diagnostic sensitivity, enabling accurate classification of essential thrombocythemia and primary myelofibrosis cases.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Methodology | Gold‑standard Sanger Sequencing + LC‑MS/MS reflex | Sanger Sequencing only |
| Diagnostic Sensitivity | 99.9% (ISO‑verified) | ~95% (lab‑dependent) |
| Turnaround Time | 5–7 calendar days | 8–14 calendar days |
| Specimen Collection | Hospital extraction only, ISO cold‑chain transport | Variable collection settings |
Physician Insight & Safety Protocols
"Identifying MPL mutations provides a critical molecular anchor in the diagnostic workup of thrombocytosis and myelofibrosis. However, no single test stands alone — results must be integrated with complete blood counts, bone marrow histology, and clinical presentation to reach an accurate diagnosis. Patients should always discuss findings with their treating hematologist before making any treatment decisions."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory & Safety Precautions
Clinical Alert
Do not discontinue any prescribed medication (including hydroxyurea, anagrelide, or antiplatelet agents) without explicit direction from your treating physician. Abrupt changes may precipitate severe thrombotic or hemorrhagic events. Always consult your hematologist before adjusting any treatment regimen.
Exclusion Criteria & Emergency Red Flags
Do Not Proceed with Collection If
- Active systemic infection or fever >38.5°C within last 48 hours.
- Platelet count <20,000/μL for bone marrow aspiration (peripheral blood substitution must be advised by physician).
- Recent blood product transfusion within the past 2 weeks (may interfere with sensitivity).
- Known allergy to local anesthetics without a physician's alternative plan.
Seek Immediate Emergency Care If You Experience
- Sudden severe limb pain, swelling, or redness (potential deep vein thrombosis).
- Neurological symptoms: acute vision loss, confusion, one‑sided weakness, or thunderclap headache.
- Uncontrolled bleeding from any site or black/tarry stools.
- Shortness of breath with pleuritic chest pain (possible pulmonary embolism).
If any exclusion criterion applies, our clinical coordinator will reschedule after physician clearance. In emergency, call 998 or proceed to the nearest DHA‑networked emergency department.
Patient FAQ & Clinical Guidance
1. What does the MPL mutation screening test detect and why is it ordered?
The MPL mutation screening identifies S505N and W515L genetic variants in the thrombopoietin receptor gene that drive abnormal bone marrow cell proliferation. This test is primarily ordered when essential thrombocythemia or primary myelofibrosis is suspected, particularly after JAK2 V617F mutation has been excluded. Hematologists and oncologists use this assay to confirm the diagnosis and guide targeted therapy decisions.
2. How is the sample collected and what should I expect during the procedure?
Sample collection is performed exclusively within a hospital setting by a qualified clinician. For bone marrow aspiration, a brief local anesthetic is administered and the procedure takes approximately 15 minutes. Peripheral blood draws follow standard venipuncture protocol. All specimens are transported under temperature-controlled conditions to the molecular genetics laboratory for analysis.
3. Is a doctor's prescription mandatory for this MPL test in the UAE?
Yes, a valid prescription from a licensed physician is required for all molecular genetic testing in the UAE, in accordance with DHA regulatory guidelines. The prescribing physician must document the clinical indication for the test. For minors, additional guardian consent is mandatory as per UAE pediatric care regulations.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic test results are handled as highly confidential medical data, with encryption protocols and access controls aligned to UAE healthcare data governance standards. Clinical safety and patient consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA facility license (No. 1143) is issued by the Dubai Health Authority, ensuring that every test meets the highest regulatory standards for diagnostic accuracy and patient safety.
Clinical & Logistical Metadata
| Test Name | Myeloproliferative Leukemia Mutation Screening (MPL – S505N; W515L) |
| Price (AED) | 900 |
| Turnaround Time | 5–7 calendar days |
| Sample Type / Matrix | Bone Marrow Aspirate or Peripheral Blood (Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety) |
| Methodology Used | Sanger Sequencing + LC‑MS/MS Reflex Confirmation |
| ICD-10-CM Code | D47.3 (Essential thrombocythemia), D47.4 (Primary myelofibrosis), D47.9 (Myeloproliferative neoplasm, unspecified) |
| LOINC Code | 92743-3 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians